title: Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.
abstract: Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be associated with increased liver fat. Our study suggests that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: T
authors.initials: T
authors.lastname: Suvitaival
authors.affiliation: Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.|Department of Psychiatry, McGill University, Montréal, QC, Canada.|Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal, QC, Canada.
authors.forename: O
authors.initials: O
authors.lastname: Mantere
authors.affiliation: Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.|Department of Psychiatry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Kieseppä
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: I
authors.initials: I
authors.lastname: Mattila
authors.affiliation: Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Pöhö
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.|Department of Chemistry, Örebro University, Örebro, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Hyötyläinen
authors.affiliation: Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Suvisaari
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.|Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Orešič
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000139:chemically induced*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000139:chemically induced*; D055432:Metabolomics; D009765:Obesity / Q000097:blood* / Q000139:chemically induced*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy*; D018570:Risk Assessment; D014280:Triglycerides / Q000097:blood*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D008055:Lipids; D014280:Triglycerides